Subscribe to RSS
DOI: 10.1055/s-0031-1277156
© Georg Thieme Verlag KG Stuttgart · New York
The Expression and Regulation of Bone-acting Cytokines in Human Peripheral Adipose Tissue in Organ Culture
Publication History
received 12.01.2011
accepted 04.04.2011
Publication Date:
10 May 2011 (online)

Abstract
The humoral cross-talk between bone and fat is an area of increasing interest. We investigated the expression and regulation of the bone-acting cytokines; bone morphogenetic protein 2 (BMP2), connective tissue growth factor (CTGF), osteoprotegerin (OPG), and transforming growth factor beta (TGFB1). Subcutaneous adipose tissue was aspirated from lean, healthy women. Tissue samples were incubated with interleukin 1-β (IL1-β), tumor necrosis factor-α (TNF-α), cortisol, troglitazone, IL1-β + troglitazone, or vehicle. Gene expression in the adipose tissue was analyzed using qPCR and protein levels in the incubation media were analyzed using ELISA. OPG expression and secretion was diminished by 40.8% and 43.1% respectively, by cortisol, and OPG expression was diminished by 67.5% by troglitazone (p<0.05). The proinflammatory cytokines IL1-β and TNF-α significantly increased the expression of CTGF (p<0.05) by 65.1% and 101.3%, respectively, and the expression and secretion of OGP by 62.3–165.8% (p<0.05). This interleukin 1-β mediated increase in CTGF- and OPG expression and secretion was ameliorated by troglitazone. Troglitazone and related drugs are known to have adverse effects on bone. We suggest that this could be mediated via altered cytokine production in adipose tissue. Moreover, obese individuals have a low-grade inflammation in their adipose tissue and have higher bone mineral density than lean individuals. We suggest that this inflammation may increase the expression and secretion of OPG and CTGF and thereby increase BMD. In conclusion, bone acting cytokines are produced in the adipose tissue and may affect bone through endocrine mechanisms.
Key words
adipose tissue - thiazolidinediones - inflammation - real-time PCR - ELISA
References
- 1
Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H.
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
N Engl J Med.
2003;
348
1656-1663
MissingFormLabel
- 2
Mirams M, Robinson BG, Mason RS, Nelson AE.
Bone as a source of FGF23: regulation by phosphate?.
Bone.
2004;
35
1192-1199
MissingFormLabel
- 3
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G.
Endocrine regulation of energy metabolism by the skeleton.
Cell.
2007;
130
456-469
MissingFormLabel
- 4
Reid IR.
Relationships among body mass, its components, and bone.
Bone.
2002;
31
547-555
MissingFormLabel
- 5
Wang MC, Bachrach LK, Van Loan M, Hudes M, Flegal KM, Crawford PB.
The relative contributions of lean tissue mass and fat mass to bone density in young
women.
Bone.
2005;
37
474-481
MissingFormLabel
- 6
Masuzaki H, Ogawa Y, Isse N, Satoh N, Okazaki T, Shigemoto M, Mori K, Tamura N, Hosoda K, Yoshimasa Y.
Human obese gene expression. Adipocyte-specific expression and regional differences
in the adipose tissue.
Diabetes.
1995;
44
855-858
MissingFormLabel
- 7
Zhao LJ, Liu YJ, Liu PY, Hamilton J, Recker RR, Deng HW.
Relationship of obesity with osteoporosis.
J Clin Endocrinol Metab.
2007;
92
1640-1646
MissingFormLabel
- 8
Bonewald LF.
Regulation and regulatory activities of transforming growth factor beta.
Crit Rev Eukaryot Gene Expr.
1999;
9
33-44
MissingFormLabel
- 9
Bonewald LF, Mundy GR.
Role of transforming growth factor-beta in bone remodeling.
Clin Orthop.
1990;
261-276
MissingFormLabel
- 10
Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC.
Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs).
J Bone Joint Surg Am.
2003;
85-A
1544-1552
MissingFormLabel
- 11
Styrkarsdottir U, Cazier JB, Kong A, Rolfsson O, Larsen H, Bjarnadottir E, Johannsdottir VD, Sigurdardottir MS, Bagger Y, Christiansen C, Reynisdottir I, Grant SF, Jonasson K, Frigge ML, Gulcher JR, Sigurdsson G, Stefansson K.
Linkage of osteoporosis to chromosome 20p12 and association to BMP2.
PLoS Biol.
2003;
1
E69
MissingFormLabel
- 12
Plikus MV, Mayer JA, de la CD, Baker RE, Maini PK, Maxson R, Chuong CM.
Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration.
Nature.
2008;
451
340-344
MissingFormLabel
- 13
Tan JT, McLennan SV, Song WW, Lo LW, Bonner JG, Williams PF, Twigg SM.
Connective tissue growth factor inhibits adipocyte differentiation.
Am J Physiol Cell Physiol.
2008;
295
C740-C751
MissingFormLabel
- 14
Hopwood B, Tsykin A, Findlay DM, Fazzalari NL.
Gene expression profile of the bone microenvironment in human fragility fracture bone.
Bone.
2009;
44
87-101
MissingFormLabel
- 15
Sims NA, Gooi JH.
Bone remodeling: Multiple cellular interactions required for coupling of bone formation
and resorption.
Semin Cell Dev Biol.
2008;
19
444-451
MissingFormLabel
- 16
Kearns AE, Khosla S, Kostenuik PJ.
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation
of bone remodeling in health and disease.
Endocr Rev.
2008;
29
155-192
MissingFormLabel
- 17
Manolagas SC.
Role of cytokines in bone resorption.
Bone.
1995;
(S 02)
63-67
MissingFormLabel
- 18
Silverman SL, Lane NE.
Glucocorticoid-induced osteoporosis.
Curr Osteoporos Rep.
2009;
7
23-26
MissingFormLabel
- 19
Murphy CE, Rodgers PT.
Effects of thiazolidinediones on bone loss and fracture.
Ann Pharmacother.
2007;
41
2014-2018
MissingFormLabel
- 20
Bruun JM, Pedersen SB, Richelsen B.
Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic
compounds, the thiazolidinedione ciglitazone and the biguanide metformin.
Horm Metab Res.
2000;
32
537-541
MissingFormLabel
- 21
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F.
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging
of multiple internal control genes.
Genome Biol.
2002;
3
RESEARCH0034
MissingFormLabel
- 22
Fu M, Zhang J, Lin YY, Zhu X, Willson TM, Chen YE.
Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin
gene expression in human aortic smooth muscle cells.
Biochem Biophys Res Commun.
2002;
294
597-601
MissingFormLabel
- 23
Zhang GY, Yi CG, Li X, Ma B, Li ZJ, Chen XL, Guo SZ, Gao WY.
Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression
in keloid fibroblasts.
Br J Dermatol.
2009;
160
762-770
MissingFormLabel
- 24
Peng Y, Liu H, Liu F, Liu Y, Li J, Chen X.
Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix
production in human peritoneal mesothelial cells.
Nephrology (Carlton).
2006;
11
516-523
MissingFormLabel
- 25
Wei JL, Peng YM, Liu F.
Connective tissue growth factor and fibronectin secretion in renal tubular epithelial
cells induced by TGF-beta1: suppressive effects of troglitazone.
Cell Biol Int.
2007;
31
30-34
MissingFormLabel
- 26
An JJ, Han DH, Kim DM, Kim SH, Rhee Y, Lee EJ, Lim SK.
Expression and regulation of osteoprotegerin in adipose tissue.
Yonsei Med J.
2007;
48
765-772
MissingFormLabel
- 27
Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouchi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y.
A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with
non-insulin dependent diabetes mellitus.
Diabetes Res Clin Pract.
1991;
11
147-153
MissingFormLabel
- 28
Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL.
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and
bone formation.
Endocrinology.
2005;
146
1226-1235
MissingFormLabel
- 29
Jones SG, Momin SR, Good MW, Shea TK, Patric K.
Distal upper and lower limb fractures associated with thiazolidinedione use.
Am J Manag Care.
2009;
15
491-496
MissingFormLabel
- 30
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
N Engl J Med.
2006;
355
2427-2443
MissingFormLabel
- 31
Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR.
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases
bone formation and bone mineral density in healthy postmenopausal women: a randomized,
controlled trial.
J Clin Endocrinol Metab.
2007;
92
1305-1310
MissingFormLabel
- 32
Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J.
The organization, promoter analysis, and expression of the human PPARgamma gene.
J Biol Chem.
1997;
272
18779-18789
MissingFormLabel
- 33
Ahdjoudj S, Fromigue O, Marie PJ.
Plasticity and regulation of human bone marrow stromal osteoprogenitor cells: potential
implication in the treatment of age-related bone loss.
Histol Histopathol.
2004;
19
151-157
MissingFormLabel
- 34
Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H.
PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone
marrow progenitors.
J Clin Invest.
2004;
113
846-855
MissingFormLabel
- 35
Wan Y, Chong LW, Evans RM.
PPAR-gamma regulates osteoclastogenesis in mice.
Nat Med.
2007;
13
1496-1503
MissingFormLabel
- 36
Cummings SR, San MJ, McCLung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C.
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
N Engl J Med.
2009;
361
756-765
MissingFormLabel
- 37
Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS.
Adipocyte death defines macrophage localization and function in adipose tissue of
obese mice and humans.
J Lipid Res.
2005;
46
2347-2355
MissingFormLabel
- 38
Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A.
Macrophages in human visceral adipose tissue: increased accumulation in obesity and
a source of resistin and visfatin.
Diabetologia.
2006;
49
744-747
MissingFormLabel
- 39
Rogowski O, Shapira I, Steinvil A, Berliner S.
Low-grade inflammation in individuals with the hypertriglyceridemic waist phenotype:
another feature of the atherogenic dysmetabolism.
Metabolism.
2009;
58
661-667
MissingFormLabel
- 40
Rizvi AA.
Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic
syndrome: emerging concepts.
Am J Med Sci.
2009;
338
310-318
MissingFormLabel
- 41
Hardy R, Cooper MS.
Bone loss in inflammatory disorders.
J Endocrinol.
2009;
201
309-320
MissingFormLabel
- 42
Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T.
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent
of the ODF/RANKL-RANK interaction.
J Exp Med.
2000;
191
275-286
MissingFormLabel
- 43
Lorenzo J, Horowitz M, Choi Y.
Osteoimmunology: interactions of the bone and immune system.
Endocr Rev.
2008;
29
403-440
MissingFormLabel
- 44
Vestergaard P, Lindholm J, Jorgensen JO, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Kristensen LO, Feldt-Rasmussen U, Mosekilde L.
Increased risk of osteoporotic fractures in patients with Cushing's syndrome.
Eur J Endocrinol.
2002;
146
51-56
MissingFormLabel
- 45
Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E.
Corticosteroid-induced bone loss in men.
J Clin Endocrinol Metab.
1998;
83
801-806
MissingFormLabel
- 46
Cooper MS.
Sensitivity of bone to glucocorticoids.
Clin Sci (Lond).
2004;
107
111-123
MissingFormLabel
- 47
Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S.
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production
by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms
of glucocorticoid-induced osteoporosis [see comments].
Endocrinology.
1999;
140
4382-4389
MissingFormLabel
- 48
Fain JN, Tagele BM, Cheema P, Madan AK, Tichansky DS.
Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese
women.
Obesity (Silver Spring).
2010;
18
890-896
MissingFormLabel
- 49
Kissebah AH, Krakower GR.
Regional adiposity and morbidity.
Physiol Rev.
1994;
74
761-811
MissingFormLabel
- 50
Vidal H.
Gene expression in visceral and subcutaneous adipose tissues.
Ann Med.
2001;
33
547-555
MissingFormLabel
- 51
Hozumi A, Osaki M, Goto H, Sakamoto K, Inokuchi S, Shindo H.
Bone marrow adipocytes support dexamethasone-induced osteoclast differentiation.
Biochem Biophys Res Commun.
2009;
382
780-784
MissingFormLabel
Correspondence
T. Harsløf
Department of Endocrinology
and Internal Medicine
Aarhus University Hospital
Tage-Hansens Gade 2
8000 Aarhus C
Denmark
Phone: +45/894/976 81
Fax: +45/894/976 84
Email: torbhars@rm.dk